{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:32:28Z","timestamp":1774002748575,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","award":["ZIACL090053"],"award-info":[{"award-number":["ZIACL090053"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","award":["ZIACL090054"],"award-info":[{"award-number":["ZIACL090054"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bbrc.2026.153355","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:39:39Z","timestamp":1769499579000},"page":"153355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NLRP3 inflammasome-mediated platelet hyperreactivity in sickle cell mice is targetable by BTK inhibition"],"prefix":"10.1016","volume":"805","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-0464","authenticated-orcid":false,"given":"Sebastian","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2403-5422","authenticated-orcid":false,"given":"Sayuri","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-5548","authenticated-orcid":false,"given":"Eric","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0354-7816","authenticated-orcid":false,"given":"Meghann","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E.F.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Zerfas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-3173","authenticated-orcid":false,"given":"Kapil","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4656-4840","authenticated-orcid":false,"given":"Christian","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-7440","authenticated-orcid":false,"given":"Michelly Sampaio","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-4368","authenticated-orcid":false,"given":"Zenaide M.N.","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153355_bib1","article-title":"High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease","volume":"9","author":"Nolfi-Donegan","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2026.153355_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mlc.2001.115450","article-title":"Thrombogenesis in sickle cell disease","volume":"137","author":"Tomer","year":"2001","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbrc.2026.153355_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103193","article-title":"Emerging pathways in thromboinflammation of sickle cell disease: novel findings in disease pathogenesis","volume":"9","author":"Ramadas","year":"2025","journal-title":"Res. Pract. Thromb Haemost."},{"key":"10.1016\/j.bbrc.2026.153355_bib4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2026.153355_bib5","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1182\/blood-2013-05-504449","article-title":"Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation","volume":"122","author":"Hottz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153355_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2025.2562267","article-title":"The NLRP3 inflammasome in platelets - form, functions, and future of the complex","volume":"36","author":"Hindle","year":"2025","journal-title":"Platelets"},{"key":"10.1016\/j.bbrc.2026.153355_bib7","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/bloodadvances.2018021709","article-title":"The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1\/TLR4 and Bruton tyrosine kinase","volume":"2","author":"Vogel","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2026.153355_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbrc.2021.03.115","article-title":"NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice","volume":"555","author":"Vogel","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.153355_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.thromres.2024.03.020","article-title":"Syk inhibition suppresses NLRP3 inflammasome activation in platelets from sickle cell mice leading to decreased platelet secretion, aggregation, spreading, and in vitro thrombus formation","volume":"237","author":"Vogel","year":"2024","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2026.153355_bib10","article-title":"Mouse models of sickle cell disease: imperfect and yet very informative","author":"Kamimura","year":"2023","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bbrc.2026.153355_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1164\/rccm.201807-1370OC","article-title":"Platelet extracellular vesicles drive Inflammasome-IL-1beta-Dependent lung injury in sickle cell disease","volume":"201","author":"Vats","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bbrc.2026.153355_bib12","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1021\/acs.jmedchem.3c01370","article-title":"Recent progress and prospects of small molecules for NLRP3 inflammasome inhibition","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.153355_bib13","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201656","article-title":"BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity","volume":"218","author":"Bittner","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.153355_bib14","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.153355_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.01.017","article-title":"Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase","author":"Liu","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bbrc.2026.153355_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbrc.2016.12.161","article-title":"The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation","volume":"483","author":"Murthy","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.153355_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.nbd.2015.10.004","article-title":"Cognitive and behavior deficits in sickle cell mice are associated with profound neuropathologic changes in hippocampus and cerebellum","volume":"85","author":"Wang","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbrc.2026.153355_bib18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/CIRCRESAHA.112.276444","article-title":"The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase\/Akt signaling","volume":"111","author":"Borst","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbrc.2026.153355_bib19","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1529\/biophysj.103.038422","article-title":"Automatic and quantitative measurement of protein-protein colocalization in live cells","volume":"86","author":"Costes","year":"2004","journal-title":"Biophys. J."},{"key":"10.1016\/j.bbrc.2026.153355_bib20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/09537104.2020.1799970","article-title":"Structural analysis of resting mouse platelets by 3D-EM reveals an unexpected variation in alpha-granule shape","volume":"32","author":"Pokrovskaya","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.bbrc.2026.153355_bib21","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1172\/JCI81660","article-title":"Platelet-derived HMGB1 is a critical mediator of thrombosis","volume":"125","author":"Vogel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.153355_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mus.26895","article-title":"Label-free histomorphometry of peripheral nerve by stimulated Raman spectroscopy","volume":"62","author":"Coto Hernandez","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbrc.2026.153355_bib23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.thromres.2014.07.035","article-title":"Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel","volume":"134","author":"Ohno","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2026.153355_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bcmd.2008.01.008","article-title":"Morphological and functional platelet abnormalities in Berkeley sickle cell mice","volume":"41","author":"Shet","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bbrc.2026.153355_bib25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.153355_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-185429","article-title":"Efficacy, safety, and biomarker analysis of 5 Mg and 7.5 Mg doses of crizanlizumab in patients with sickle cell disease: primary analyses from the phase III STAND study","volume":"142","author":"Abboud Rd","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.153355_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events","volume":"374","author":"Heeney","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.153355_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105835","article-title":"Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3)","volume":"85","author":"Heeney","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.bbrc.2026.153355_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.15117","article-title":"Platelets at the crossroads of thrombosis, inflammation and haemolysis","volume":"180","author":"Vogel","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2026.153355_bib30","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2025-2975","article-title":"A randomized, double-blind, placebo-controlled trial of a novel BTK inhibitor (rilzabrutinib) in patients with sickle cell disease (SCD) aged 10\u201365 years: LIBRA study","volume":"146","author":"Ataga","year":"2025","journal-title":"Blood"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:03:36Z","timestamp":1773993816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"alternative-id":["S0006291X26001191"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153355","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NLRP3 inflammasome-mediated platelet hyperreactivity in sickle cell mice is targetable by BTK inhibition","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153355"}}